Huland H - Search Results

1

Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database.

Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, Shariat SF, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Preisser F, et al. Among authors: huland h. Eur Urol Focus. 2019 Sep;5(5):807-814. doi: 10.1016/j.euf.2018.05.006. Epub 2018 May 22. Eur Urol Focus. 2019. PMID: 29802052

2

Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma.

Conrad S, Graefen M, Pichlmeier U, Henke RP, Erbersdobler A, Hammerer PG, Huland H. Conrad S, et al. Among authors: huland h. J Urol. 2002 Feb;167(2 Pt 1):521-5. doi: 10.1016/S0022-5347(01)69077-3. J Urol. 2002. PMID: 11792910

3

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.

Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H. Graefen M, et al. Among authors: huland e, huland h. J Urol. 2002 Mar;167(3):1306-9. J Urol. 2002. PMID: 11832719

4

Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?

Cagiannos I, Graefen M, Karakiewicz PI, Ohori M, Eastham JA, Rabbani F, Fair W, Wheeler TM, Hammerer PG, Haese A, Erbersdobler A, Huland H, Scardino PT, Kattan MW. Cagiannos I, et al. Among authors: huland h. J Clin Oncol. 2002 Apr 15;20(8):2025-30. doi: 10.1200/JCO.2002.08.123. J Clin Oncol. 2002. PMID: 11956261

5

Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone.

Erbersdobler A, Fritz H, Schnöger S, Graefen M, Hammerer P, Huland H, Henke RP. Erbersdobler A, et al. Among authors: huland h. Eur Urol. 2002 Jan;41(1):40-6. doi: 10.1016/s0302-2838(01)00021-5. Eur Urol. 2002. PMID: 11999464

6

Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer.

Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H. Palisaar RJ, et al. Among authors: huland e, huland h. Eur Urol. 2002 Feb;41(2):155-61. doi: 10.1016/s0302-2838(01)00025-2. Eur Urol. 2002. PMID: 12074402

7

Prediction of tumor heterogeneity in localized prostate cancer.

Huland H, Graefen M, Haese A, Hammerer PG, Palisaar J, Pichlmeier U, Henke RP, Erbersdobler A, Huland E, Lilja H. Huland H, et al. Among authors: huland e. Urol Clin North Am. 2002 Feb;29(1):213-22. doi: 10.1016/s0094-0143(02)00006-x. Urol Clin North Am. 2002. PMID: 12109347 Review.

8

Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.

Friedrich MG, Hellstern A, Hautmann SH, Graefen M, Conrad S, Huland E, Huland H. Friedrich MG, et al. Among authors: huland e, huland h. J Urol. 2002 Aug;168(2):470-4. doi: 10.1016/s0022-5347(05)64660-5. J Urol. 2002. PMID: 12131290

9

International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.

Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW. Graefen M, et al. Among authors: huland h. J Clin Oncol. 2002 Aug 1;20(15):3206-12. doi: 10.1200/JCO.2002.12.019. J Clin Oncol. 2002. PMID: 12149292

10

Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy.

Noldus J, Michl U, Graefen M, Haese A, Hammerer P, Huland H. Noldus J, et al. Among authors: huland h. Eur Urol. 2002 Aug;42(2):118-24. doi: 10.1016/s0302-2838(02)00219-1. Eur Urol. 2002. PMID: 12160581

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

714 results

Search Page

Filters